Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MEXICO ONCOLOGY DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER'S FIVE FORCES ANALYSIS
4.3 PIPELINE ANALYSIS — MEXICO ONCOLOGY DRUGS MARKET
4.3.1 PHASE DISTRIBUTION
4.3.2 KEY TRENDS IN THE EXPANDED PIPELINE
4.3.3 GEOGRAPHICAL AND INSTITUTIONAL TRENDS
4.3.4 STRATEGIC INSIGHTS
4.4 MERGERS AND ACQUISITIONS
4.4.1 LICENSING
4.4.2 COMMERCIALIZATION AGREEMENTS
4.5 DRUG TREATMENT RATE IN MATURED MARKETS
4.5.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.5.2 PATIENT FLOW DIAGRAM
4.5.3 KEY PRICING STRATEGIES
4.5.4 KEY PATIENT ENROLLMENT STRATEGIES
4.5.5 INTERVIEWS WITH SPECIALISTS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 PATIENT TREATMENT SUCCESS RATES
6 REGULATION COVERAGE.
6.1 NORTH AMERICA
6.1.1 PRODUCT CODES
6.1.2 CERTIFIED STANDARDS
6.1.3 SAFETY STANDARDS
6.1.3.1 MATERIAL HANDLING & STORAGE
6.1.3.2 TRANSPORT & PRECAUTIONS
6.1.3.3 HAZARD IDENTIFICATION
6.1.4 REGULATION COVERAGE – MEXICO ONCOLOGY DRUGS MARKET
6.1.4.1 PRODUCT CODES
6.1.4.2 CERTIFIED STANDARDS
6.1.5 SAFETY STANDARDS
6.1.5.1 MATERIAL HANDLING & STORAGE
6.1.5.2 TRANSPORT & PRECAUTIONS
6.1.5.3 1HAZARD IDENTIFICATION
6.1.6 VARIATION IN REGULATIONS BASED ON ONCOLOGY DRUG TYPES
6.1.6.1 SMALL MOLECULE CHEMOTHERAPY AGENTS
6.1.7 BIOLOGICS (MONOCLONAL ANTIBODIES, CYTOKINES, CELL-BASED THERAPIES)
6.1.7.1 BIOSIMILARS
6.1.7.2 IMMUNOTHERAPIES (CHECKPOINT INHIBITORS, CYTOKINE THERAPIES)
6.1.7.3 ADVANCED THERAPIES (GENE THERAPY, CAR-T CELLS)
7 MEXICO ONCOLOGY DRUG MARKET: MARKET OVERVIEW
7.1 DRIVER
7.1.1 INCREASED ADOPTION OF IMMUNOTHERAPY & NEW TREATMENT REGIMENS
7.1.2 RISING CANCER INCIDENCE AND MORTALITY
7.1.3 GROWING AWARENESS & CLINICAL EVIDENCE
7.2 RESTRAINTS
7.2.1 HIGH COST AND AFFORDABILITY
7.2.2 FRAGMENTED AND UNDER-RESOURCED HEALTH SYSTEM
7.2.3 SUPPLY CHAIN ISSUES AND DRUG SHORTAGES
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN ONCOLOGY DRUG DEVELOPMENT AND DELIVERY
7.3.4 STRINGENT RULES & REGULATIONS
7.3.5 LIMITED ACCESS, INFRASTRUCTURE, AND DISTRIBUTION OF ONCOLOGY DRUGS
7.3.6 ECONOMIC AND INSTITUTIONAL CHALLENGES IN MARKET SUSTAINABILITY
8 MEXICO ONCOLOGY DRUGS MARKET, BY DRUG CLASS
8.1 OVERVIEW
8.2 TARGETED DRUGS
8.2.1 MONOCLONAL ANTIBODIES
8.2.1.1 TRASTUZUMAB
8.2.1.2 BEVACIZUMAB
8.2.1.3 RITUXIMAB
8.2.1.4 OFATUMUMAB
8.2.1.5 OBINUTUZUMAB
8.2.1.6 ALEMTUZUMAB
8.2.1.7 OTHERS
8.2.2 TYROSINE KINASE INHIBITORS
8.2.2.1 IMATINIB
8.2.2.2 DASATINIB
8.2.2.3 NILOTINIB
8.2.2.4 BOSUTINIB
8.2.2.5 SUNITINIB
8.2.2.6 PONATINIB
8.2.2.7 OTHERS
8.2.3 PROTEASOME INHIBITOR
8.2.3.1 BORTEZOMIB
8.2.3.2 CARFILZOMIB
8.2.3.3 OTHERS
8.2.4 OTHERS
8.3 CYTOTOXIC DRUGS
8.3.1 ALKYLATING AGENT
8.3.1.1 CISPLATIN
8.3.1.2 CARBOPLATIN
8.3.1.3 CYCLOPHOSPHAMIDE
8.3.1.4 MELPHALAN
8.3.1.5 CHLORAMBUCIL
8.3.1.6 OTHERS
8.3.2 ANTIMETABOLITES
8.3.2.1 METHOTREXATE
8.3.2.2 FLUOROURACIL
8.3.2.3 GEMCITABINE
8.3.2.4 CYTARABINE (ARA-C)
8.3.2.5 AZACITIDINE
8.3.2.6 FLUDARABINE
8.3.2.7 OTHERS
8.3.3 ANTIMITOTIC DRUGS
8.3.3.1 VINCRISTINE
8.3.3.2 VINBLASTINE
8.3.3.3 CABAZITAXEL
8.3.3.4 OTHERS
8.3.4 TOPOISOMERASE INHIBITORS (I AND II)
8.3.4.1 ANTHRACYCLINE
8.3.4.1.1 DOXORUBICIN
8.3.4.1.2 DAUNORUBICIN
8.3.4.1.3 IDARUBICIN
8.3.4.1.4 OTHERS
8.3.4.2 ETOPOSIDE
8.3.4.3 IRINOTECAN
8.3.4.4 TOPOTECAN
8.3.4.5 OTHERS
8.4 IMMUNOTHERAPY
8.4.1 CAR T-CELL THERAPY
8.4.1.1 AXICABTAGENE CILOLEUCEL
8.4.1.2 TISAGENLECLEUCEL
8.4.1.3 BREXUCABTAGENE AUTOLEUCEL
8.4.1.4 OTHERS
8.4.2 IMMUNOMODULATORY DRUGS (IMIDS)
8.4.2.1 LENALIDOMIDE
8.4.2.2 POMALIDOMIDE
8.4.2.3 THALIDOMIDE
8.4.3 CYTOKINES
8.4.3.1 INTERFERONS
8.4.3.1.1 INTERFERON ALFA-2B
8.4.3.1.2 INTERFERON ALFA-2A
8.4.3.2 INTERLEUKINS (ILS)
8.4.4 OTHERS
8.5 HORMONAL DRUGS
8.5.1 SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)
8.5.1.1 TAMOXIFEN (NOLVADEX)
8.5.1.2 TOREMIFENE (FARESTON)
8.5.2 ESTROGEN PRODUCTION BLOCKERS
8.5.2.1 LETROZOLE
8.5.2.2 ANASTROZOLE
8.5.2.3 EXEMESTANE
8.5.2.4 OTHERS
8.5.3 OTHER ANTIESTROGEN DRUGS
8.5.4 OVARIAN FUNCTION BLOCKERS
8.5.4.1 GOSERELIN
8.5.4.2 LEUPRORELIN
8.5.4.3 TRIPTORELIN
8.6 OTHERS
9 MEXICO ONCOLOGY DRUGS MARKET, BY DRUGS TYPE
9.1 OVERVIEW
9.2 BRANDED
9.3 GENERICS
10 MEXICO ONCOLOGY DRUGS MARKET, BY TYPE
10.1 OVERVIEW
10.2 LUNG CANCER
10.2.1 TARGETED DRUGS
10.2.2 CYTOTOXIC DRUGS
10.2.3 IMMUNOTHERAPY
10.2.4 HORMONAL DRUGS
10.3 BREAST CANCER
10.3.1 TARGETED DRUGS
10.3.2 HORMONAL DRUGS
10.3.3 CYTOTOXIC DRUGS
10.3.4 IMMUNOTHERAPY
10.4 BLOOD CANCER
10.4.1 LEUKEMIA
10.4.2 NON-HODGKIN LYMPHOMA
10.4.3 MULTIPLE MYELOMA
10.4.4 HODGKIN LYMPHOMA
10.4.5 TARGETED DRUGS
10.4.6 CYTOTOXIC DRUGS
10.4.7 IMMUNOTHERAPY
10.4.8 HORMONAL DRUGS
10.5 COLORECTAL CANCER
10.5.1 IMMUNOTHERAPY
10.5.2 CYTOTOXIC DRUGS
10.5.3 TARGETED DRUGS
10.5.4 HORMONAL DRUGS
10.6 PROSTATE CANCER
10.6.1 HORMONAL DRUGS
10.6.2 TARGETED DRUGS
10.6.3 CYTOTOXIC DRUGS
10.6.4 IMMUNOTHERAPY
10.7 LIVER CANCER
10.7.1 TARGETED DRUGS
10.7.2 CYTOTOXIC DRUGS
10.7.3 IMMUNOTHERAPY
10.7.4 HORMONAL DRUGS
10.8 PANCREATIC CANCER
10.8.1 TARGETED DRUGS
10.8.2 CYTOTOXIC DRUGS
10.8.3 IMMUNOTHERAPY
10.8.4 HORMONAL DRUGS
10.9 KIDNEY CANCER
10.9.1 TARGETED DRUGS
10.9.2 CYTOTOXIC DRUGS
10.9.3 IMMUNOTHERAPY
10.9.4 HORMONAL DRUGS
10.1 GASTRIC CANCER
10.10.1 CYTOTOXIC DRUGS
10.10.2 TARGETED DRUGS
10.10.3 IMMUNOTHERAPY
10.10.4 HORMONAL DRUGS
10.11 ENDOMETRIAL CANCER
10.11.1 CYTOTOXIC DRUGS
10.11.2 TARGETED DRUGS
10.11.3 HORMONAL DRUGS
10.11.4 IMMUNOTHERAPY
10.12 THYROID CANCER
10.12.1 TARGETED DRUGS
10.12.2 CYTOTOXIC DRUGS
10.12.3 IMMUNOTHERAPY
10.12.4 HORMONAL DRUGS
10.13 OTHERS
10.13.1 TARGETED DRUGS
10.13.2 CYTOTOXIC DRUGS
10.13.3 IMMUNOTHERAPY
10.13.4 HORMONAL DRUGS
11 MEXICO ONCOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 PARENTERAL
11.3 ORAL
11.3.1 TABLETS
11.3.2 CAPSULE
11.3.3 PILL
11.3.4 OTHERS
12 MEXICO ONCOLOGY DRUGS MARKET, BY POPULATION TYPE
12.1 OVERVIEW
12.2 GERIATRIC
12.3 ADULTS
12.4 CHILDREN
13 MEXICO ONCOLOGY DRUGS MARKET, BY GENDER
13.1 OVERVIEW
13.2 MALE
13.3 FEMALE
14 MEXICO ONCOLOGY DRUGS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITAL
14.2.1 PUBLIC
14.2.2 PRIVATE
14.3 SPECIALTY CLINICS
14.4 AMBULATORY SURGICAL CENTERS
14.5 HOME HEALTHCARE
14.6 OTHERS
15 MEXICO ONCOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
15.3.1 HOSPITALS PHARMACY
15.3.2 RETAIL PHARMACY
15.3.3 ONLINE PHARMACY
15.4 OTHERS
16 MEXICO ONCOLOGY DRUGS MARKET, COMPANY LANDSCAPE
16.1 MANUFACTURER COMPANY SHARE ANALYSIS: MEXICO
16.2 DISTRIBUTOR COMPANY SHARE ANALYSIS: MEXICO
17 SWOT ANALYSIS
18 COMPANY PROFILES
18.1 ASTRAZENECA
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENT
18.2 PFIZER INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 PRODUCT PORTFOLIO
18.2.4 RECENT DEVELOPMENT
18.3 BRISTOL-MYERS SQUIBB COMPANY
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT NEWS
18.4 ESTEVE
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENT
18.5 NOVARTIS AG
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 F. HOFFMANN-LA ROCHE LTD.
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 MERCK & CO., INC.
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 ABBVIE INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 AMGEN INC.
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 ARCHIMED
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENTS
18.11 ASTELLAS PHARMA INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.12 BAYER AG
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENT
18.13 BEONE MEDICINES
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 BOEHRINGER INGELHEIM GMBH
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 DAIICHI SANKYO COMPANY, LIMITED.
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 EISAI CO., LTD.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 FANASA
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENTS
18.18 FLORENCIA HEALTHCARE
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENT
18.19 GLENMARK PHARMACEUTICALS LTD.
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENTS
18.2 IPSEN PHARMA
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENT
18.21 JOHNSON & JOHNSON AND ITS AFFILIATES
18.21.1 COMPANY SNAPSHOT
18.21.2 REVENUE ANALYSIS
18.21.3 PRODUCT PORTFOLIO
18.21.4 RECENT DEVELOPMENT/NEWS
18.22 KNIGHT THERAPEUTICS INC.
18.22.1 COMPANY SNAPSHOT
18.22.2 REVENUE ANALYSIS
18.22.3 PRODUCT PORTFOLIO
18.22.4 RECENT DEVELOPMENTS
18.23 MARZAM
18.23.1 COMPANY SNAPSHOT
18.23.2 PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENTS
18.24 NADRO
18.24.1 COMPANY SNAPSHOT
18.24.2 PRODUCT PORTFOLIO
18.24.3 RECENT DEVELOPMENTS
18.25 ONCO ESPECIALIZADOS
18.25.1 COMPANY SNAPSHOT
18.25.2 PRODUCT PORTFOLIO
18.25.3 RECENT DEVELOPMENT
18.26 PISA
18.26.1 COMPANY SNAPSHOT
18.26.2 PRODUCT PORTFOLIO
18.26.3 RECENT DEVELOPMENTS
18.27 PROBEMEDIC DISTRIBUCIONES, SA DE CV
18.27.1 COMPANY SNAPSHOT
18.27.2 PRODUCT PORTFOLIO
18.27.3 RECENT DEVELOPMENT
18.28 SANOFI
18.28.1 COMPANY SNAPSHOT
18.28.2 REVENUE ANALYSIS
18.28.3 PRODUCT PORTFOLIO
18.28.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
TABLE 1 MEXICO ONCOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 2 MEXICO TARGETED DRUGS IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 3 MEXICO MONOCLONAL ANTIBODIES IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 4 MEXICO TYROSINE KINASE INHIBITORS IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 5 MEXICO PROTEASOME INHIBITOR IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 MEXICO CYTOTOXIC DRUGS IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 MEXICO ALKYLATING AGENT IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 MEXICO ANTIMETABOLITES IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 MEXICO ANTIMITOTIC DRUGS IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 10 MEXICO TOPOISOMERASE INHIBITORS (I AND II) IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 MEXICO ANTHRACYCLINES IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 MEXICO IMMUNOTHERAPY IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 MEXICO CAR T-CELL THERAPY IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 MEXICO IMMUNOMODULATORY DRUGS (IMIDS) IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 MEXICO CYTOKINES IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 MEXICO INTERFERONS IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 17 MEXICO HORMONAL DRUGS IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 18 MEXICO SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 19 MEXICO ESTROGEN PRODUCTION BLOCKERS IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 20 MEXICO OVARIAN FUNCTION BLOCKERS IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 MEXICO ONCOLOGY DRUGS MARKET, BY DRUGS TYPE, 2018-2032 (USD THOUSAND)
TABLE 22 MEXICO ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 23 MEXICO LUNG CANCER IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 24 MEXICO BREAST CANCER IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 25 MEXICO BLOOD CANCER IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 26 MEXICO BLOOD CANCER IN ONCOLOGY DRUGS MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 27 MEXICO COLORECTAL CANCER IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 28 MEXICO PROSTATE CANCER IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 MEXICO LIVER CANCER IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 MEXICO PANCREATIC CANCER IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 31 MEXICO KIDNEY CANCER IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 32 MEXICO GASTRIC CANCER IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 33 MEXICO ENDOMETRIAL CANCER IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 MEXICO THYROID CANCER IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 MEXICO OTHERS IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 MEXICO ONCOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 37 MEXICO ORAL IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 38 MEXICO ONCOLOGY DRUGS MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 39 MEXICO ONCOLOGY DRUGS MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 40 MEXICO ONCOLOGY DRUGS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 41 MEXICO HOSPITAL IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 MEXICO ONCOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 43 MEXICO RETAIL SALES IN ONCOLOGY DRUGS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 MEXICO ONCOLOGY DRUGS MARKET: SEGMENTATION
FIGURE 2 MEXICO ONCOLOGY DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 MEXICO ONCOLOGY DRUGS MARKET: DROC ANALYSIS
FIGURE 4 MEXICO ONCOLOGY DRUGS MARKET: GLOBAL VS REGIONAL ANALYSIS
FIGURE 5 MEXICO ONCOLOGY DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MEXICO ONCOLOGY DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MEXICO ONCOLOGY DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MEXICO ONCOLOGY DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 MEXICO ONCOLOGY DRUGS MARKET: SEGMENTATION
FIGURE 10 EXECUTIVE SUMMARY
FIGURE 11 STRATEGIC DECISIONS
FIGURE 12 FOUR SEGMENTS COMPRISE THE MEXICO ONCOLOGY DRUGS MARKET, BY DRUG CLASS
FIGURE 13 INCREASING CONSUMER AWARENESS OF NATURAL HEALTH SOLUTIONS EXPECTED TO DRIVE THE MEXICO ONCOLOGY DRUGS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MEXICO ONCOLOGY DRUGS MARKET IN 2025 & 2032
FIGURE 15 DROC ANALYSIS
FIGURE 16 MEXICO ONCOLOGY DRUGS MARKET: BY DRUG CLASS, 2024
FIGURE 17 MEXICO ONCOLOGY DRUGS MARKET: BY DRUG CLASS, 2025 TO 2032 (USD THOUSAND)
FIGURE 18 MEXICO ONCOLOGY DRUGS MARKET: BY DRUG CLASS, CAGR (2025- 2032)
FIGURE 19 MEXICO ONCOLOGY DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE
FIGURE 20 MEXICO ONCOLOGY DRUGS MARKET: BY DRUGS TYPE, 2024
FIGURE 21 MEXICO ONCOLOGY DRUGS MARKET: BY DRUGS TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 22 MEXICO ONCOLOGY DRUGS MARKET: BY DRUGS TYPE, CAGR (2025- 2032)
FIGURE 23 MEXICO ONCOLOGY DRUGS MARKET: BY DRUGS TYPE, LIFELINE CURVE
FIGURE 24 MEXICO ONCOLOGY DRUGS MARKET: BY TYPE, 2024
FIGURE 25 MEXICO ONCOLOGY DRUGS MARKET: BY TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 26 MEXICO ONCOLOGY DRUGS MARKET: BY TYPE, CAGR (2025- 2032)
FIGURE 27 MEXICO ONCOLOGY DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 28 MEXICO ONCOLOGY DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2024
FIGURE 29 MEXICO ONCOLOGY DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 30 MEXICO ONCOLOGY DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025- 2032)
FIGURE 31 MEXICO ONCOLOGY DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 32 MEXICO ONCOLOGY DRUGS MARKET: BY POPULATION TYPE, 2024
FIGURE 33 MEXICO ONCOLOGY DRUGS MARKET: BY POPULATION TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 34 MEXICO ONCOLOGY DRUGS MARKET: BY POPULATION TYPE, CAGR (2025- 2032)
FIGURE 35 MEXICO ONCOLOGY DRUGS MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 36 MEXICO ONCOLOGY DRUGS MARKET: BY GENDER, 2024
FIGURE 37 MEXICO ONCOLOGY DRUGS MARKET: BY GENDER, 2025 TO 2032 (USD THOUSAND)
FIGURE 38 MEXICO ONCOLOGY DRUGS MARKET: BY GENDER, CAGR (2025- 2032)
FIGURE 39 MEXICO ONCOLOGY DRUGS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 40 MEXICO ONCOLOGY DRUGS MARKET: BY END USER, 2024
FIGURE 41 MEXICO ONCOLOGY DRUGS MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 42 MEXICO ONCOLOGY DRUGS MARKET: BY END USER, CAGR (2025- 2032)
FIGURE 43 MEXICO ONCOLOGY DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 MEXICO ONCOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 45 MEXICO ONCOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 46 MEXICO ONCOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)
FIGURE 47 MEXICO ONCOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 MEXICO ONCOLOGY DRUGS MARKET: COMPANY SHARE 2024 (%)
FIGURE 49 MEXICO ONCOLOGY DRUGS MARKET: COMPANY SHARE 2024 (%)
